Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses
AssigneeMagnesium Diagnostics, Inc.
InventorIbert C. Wells
Life of this patent
Estimating the term…
Abstract
This invention relates to methods for detecting the deficiency of magnesium tightly bound to cellular membranes, i.e., magnesium binding defect, which deficiency is associated with certain abnormal physiological states, e.g., salt-sensitive essential hypertension or Type 2 diabetes mellitus.
Claims20
A monoclonal or polyclonal antibody having high affinity for a peptide selected from the group consisting of:
- Phe-Phe-Gly-Leu-Met-NH2 (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH2, where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH2 (SEQ ID NO:2).
A method for detecting magnesium binding defect comprising:
- a) measuring in blood serum the level of peptide having an amino acid sequence selected from the group consisting of:
- Phe-Phe-Gly-Leu-Met-NH2 (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH2, where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH2 (SEQ ID NO:2);
- and
- b) comparing said level to a standard,
- wherein a reduced level of said peptide is indicative of said magnesium binding defect.
A method for correcting magnesium binding defect of an individual comprising administering to said individual peptide having an amino acid sequence selected from the group consisting of:
- Phe-Phe-Gly-Leu-Met-NH2 (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH2, where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH2 (SEQ ID NO:2).
Dependencies are inferred from the claim text.